Treatment of chronic hepatitis C virus infection at the beginning of a new era
Urbánek, P.
Vnitrni Lekarstvi 59(7): 612-617
2013
ISSN/ISBN: 0042-773X PMID: 23909268 Document Number: 666154
After 2010 the therapy of chronic HCV infection entered a completely new era - the era that is marked with the gradual introduction of the so-called directly acting antivirals into treatment schemes of this serious disease. The term directly acting antivirals (DAA) covers low-molecular substances that inhibit viral nonstructural proteins - enzymes involved in the HCV replication cycle. At present, the first 2 representatives of DAA, Boceprevir and Telaprevir, have been approved for chronic HCV infection indication. The synoptic article pays the greatest attention to these 2 representatives, along with mentioning some other substances that are under later phases of clinical development and are likely to be approved in the near future.